Theraclion SA

Chart & Performance

D1W1MN

P/E

—

P/S

0.00

EPS

—

Div Yield, %

—

Shrs. gr., 5y

29.88%

Rev. gr., 5y

9.77%

Revenues

+42.84%

Net income

-6m

L-1.20%

CFO

-7m

L+145.93%

Earnings

Oct 26, 2026

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Theraclion SA specializes in developing advanced echotherapy devices that harness high-intensity focused ultrasound technology. Its product portfolio includes SONOVEIN, a robotic, non-surgical echotherapy system specifically designed for treating varicose veins. Another key offering is ECHOPULSE, also a robotic and non-invasive echotherapy solution, utilized for addressing thyroid nodules and breast fibroadenomas. The company further provides EPack, a disposable accessory that attaches to the treatment device to ensure patient skin protection and improve imaging precision. Founded in 2004, Theraclion SA is headquartered in Malakoff, France.

URL

https://www.theraclion.fr/

IPO date

Apr 25, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT